Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 416 entries
Sorted by: Best Match Show Resources per page
Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study.

Current therapeutic research, clinical and experimental

Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S.
PMID: 24672118
Curr Ther Res Clin Exp. 2005 Mar;66(2):117-29. doi: 10.1016/j.curtheres.2005.04.002.

BACKGROUND: The Recover Study is an ongoing, prospective study designed 10 to assess toxicity associated with the use of nucleoside analogue reverse transcriptase inhibitors (NRTIs) (stavudine, zidovudine, lamivudine, didanosine, abacavir) in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART)...

Cite
Palacios R, Santos J, Camino X, et al. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp. 2005;66(2):117-29doi: 10.1016/j.curtheres.2005.04.002.
Palacios, R., Santos, J., Camino, X., Arazo, P., Torres Perea, R., Echevarrfa, S., Ribera, E., Sánchez de la Rosa, R., Moreno Guillen, S. (2005). Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Current therapeutic research, clinical and experimental, 66(2), 117-29. https://doi.org/10.1016/j.curtheres.2005.04.002
Palacios, Rosario, et al. "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study." Current therapeutic research, clinical and experimental vol. 66,2 (2005): 117-29. doi: https://doi.org/10.1016/j.curtheres.2005.04.002
Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp. 2005 Mar;66(2):117-29. doi: 10.1016/j.curtheres.2005.04.002. PMID: 24672118; PMCID: PMC3964549.
Copy Download .nbib Format: NLM
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

SAGE open medicine

Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Van Baelen B, Vanveggel S, Opsomer M.
PMID: 28382208
SAGE Open Med. 2017 Jan 18;5:2050312116686482. doi: 10.1177/2050312116686482. eCollection 2017.

OBJECTIVE: VIOLIN (TMC125IFD3002; NCT01422330) evaluated the safety, tolerability, and pharmacokinetics of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected patients.METHODS: In a 48-week, phase IV, single-arm, multicenter study, patients on prior antiretroviral therapy (⩾8 weeks) who needed to change...

Cite
Arathoon E, Bhorat A, Silaghi R, et al. Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. SAGE Open Med. 2017;5:2050312116686482doi: 10.1177/2050312116686482.
Arathoon, E., Bhorat, A., Silaghi, R., Crauwels, H., Lavreys, L., Tambuyzer, L., Van Baelen, B., Vanveggel, S., & Opsomer, M. (2017). Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. SAGE open medicine, 52050312116686482. https://doi.org/10.1177/2050312116686482
Arathoon, Eduardo, et al. "Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial." SAGE open medicine vol. 5 (2017): 2050312116686482. doi: https://doi.org/10.1177/2050312116686482
Arathoon E, Bhorat A, Silaghi R, Crauwels H, Lavreys L, Tambuyzer L, Van Baelen B, Vanveggel S, Opsomer M. Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial. SAGE Open Med. 2017 Jan 18;5:2050312116686482. doi: 10.1177/2050312116686482. eCollection 2017. PMID: 28382208; PMCID: PMC5367767.
Copy Download .nbib Format: NLM
Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.

The lancet. HIV

Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, Bennett D, Raizes E, Nakagawa F, De Luca A, Vitoria M, Barcarolo J, Perriens J, Jordan MR, Bertagnolio S.
PMID: 26423990
Lancet HIV. 2014 Nov;1(2):e85-93. doi: 10.1016/S2352-3018(14)70021-9. Epub 2014 Oct 14.

BACKGROUND: With continued roll-out of antiretroviral therapy (ART) in resource-limited settings, evidence is emerging of increasing levels of transmitted drug-resistant HIV. We aimed to compare the effectiveness and cost-effectiveness of different potential public health responses to substantial levels of...

Cite
Phillips AN, Cambiano V, Miners A, et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV. 2014;1(2):e85-93doi: 10.1016/S2352-3018(14)70021-9.
Phillips, A. N., Cambiano, V., Miners, A., Revill, P., Pillay, D., Lundgren, J. D., Bennett, D., Raizes, E., Nakagawa, F., De Luca, A., Vitoria, M., Barcarolo, J., Perriens, J., Jordan, M. R., & Bertagnolio, S. (2014). Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. The lancet. HIV, 1(2), e85-93. https://doi.org/10.1016/S2352-3018(14)70021-9
Phillips, Andrew N, et al. "Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis." The lancet. HIV vol. 1,2 (2014): e85-93. doi: https://doi.org/10.1016/S2352-3018(14)70021-9
Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, Bennett D, Raizes E, Nakagawa F, De Luca A, Vitoria M, Barcarolo J, Perriens J, Jordan MR, Bertagnolio S. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV. 2014 Nov;1(2):e85-93. doi: 10.1016/S2352-3018(14)70021-9. Epub 2014 Oct 14. PMID: 26423990; PMCID: PMC4822192.
Copy Download .nbib Format: NLM
Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection.

World journal of clinical cases

Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP.
PMID: 28255546
World J Clin Cases. 2017 Feb 16;5(2):40-45. doi: 10.12998/wjcc.v5.i2.40.

A 54-year-old black African woman, 22 years human immunodeficiency virus (HIV)-positive, presented with an acute coronary syndrome. She was taking two nucleoside reverse transcriptase inhibitors and two protease inhibitors. Viral load and CD4 count were stable. Angiography revealed a...

Cite
Alkhalil M, Conlon CP, Ashrafian H, et al. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases. 2017;5(2):40-45doi: 10.12998/wjcc.v5.i2.40.
Alkhalil, M., Conlon, C. P., Ashrafian, H., & Choudhury, R. P. (2017). Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World journal of clinical cases, 5(2), 40-45. https://doi.org/10.12998/wjcc.v5.i2.40
Alkhalil, Mohammad, et al. "Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection." World journal of clinical cases vol. 5,2 (2017): 40-45. doi: https://doi.org/10.12998/wjcc.v5.i2.40
Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases. 2017 Feb 16;5(2):40-45. doi: 10.12998/wjcc.v5.i2.40. PMID: 28255546; PMCID: PMC5314259.
Copy Download .nbib Format: NLM
Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs.

Beilstein journal of organic chemistry

Chiodo F, Marradi M, Calvo J, Yuste E, Penadés S.
PMID: 24991287
Beilstein J Org Chem. 2014 Jun 12;10:1339-46. doi: 10.3762/bjoc.10.136. eCollection 2014.

The therapeutic approach for the treatment of HIV infection is based on the highly active antiretroviral therapy (HAART), a cocktail of antiretroviral drugs. Notwithstanding HAART has shown different drawbacks like toxic side effects and the emergence of viral multidrug...

Cite
Chiodo F, Marradi M, Calvo J, et al. Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein J Org Chem. 2014;10:1339-46doi: 10.3762/bjoc.10.136.
Chiodo, F., Marradi, M., Calvo, J., Yuste, E., & Penadés, S. (2014). Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein journal of organic chemistry, 101339-46. https://doi.org/10.3762/bjoc.10.136
Chiodo, Fabrizio, et al. "Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs." Beilstein journal of organic chemistry vol. 10 (2014): 1339-46. doi: https://doi.org/10.3762/bjoc.10.136
Chiodo F, Marradi M, Calvo J, Yuste E, Penadés S. Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein J Org Chem. 2014 Jun 12;10:1339-46. doi: 10.3762/bjoc.10.136. eCollection 2014. PMID: 24991287; PMCID: PMC4077455.
Copy Download .nbib Format: NLM
The Δ133p53 Isoform Reduces Wtp53-induced Stimulation of DNA Pol γ Activity in the Presence and Absence of D4T.

Aging and disease

Liu K, Zang Y, Guo X, Wei F, Yin J, Pang L, Chen D.
PMID: 28400988
Aging Dis. 2017 Apr 01;8(2):228-239. doi: 10.14336/AD.2016.0910. eCollection 2017 Apr.

The mitochondrial toxicity of nucleoside reverse transcriptase inhibitors (NRTIs) is due to the inhibition of mitochondrial DNA (mtDNA) polymerase γ (pol γ). Previous studies have shown that wild type p53 (wtp53) can interact with pol γ and mtDNA to...

Cite
Liu K, Zang Y, Guo X, et al. The Δ133p53 Isoform Reduces Wtp53-induced Stimulation of DNA Pol γ Activity in the Presence and Absence of D4T. Aging Dis. 2017;8(2):228-239doi: 10.14336/AD.2016.0910.
Liu, K., Zang, Y., Guo, X., Wei, F., Yin, J., Pang, L., & Chen, D. (2017). The Δ133p53 Isoform Reduces Wtp53-induced Stimulation of DNA Pol γ Activity in the Presence and Absence of D4T. Aging and disease, 8(2), 228-239. https://doi.org/10.14336/AD.2016.0910
Liu, Kai, et al. "The Δ133p53 Isoform Reduces Wtp53-induced Stimulation of DNA Pol γ Activity in the Presence and Absence of D4T." Aging and disease vol. 8,2 (2017): 228-239. doi: https://doi.org/10.14336/AD.2016.0910
Liu K, Zang Y, Guo X, Wei F, Yin J, Pang L, Chen D. The Δ133p53 Isoform Reduces Wtp53-induced Stimulation of DNA Pol γ Activity in the Presence and Absence of D4T. Aging Dis. 2017 Apr 01;8(2):228-239. doi: 10.14336/AD.2016.0910. eCollection 2017 Apr. PMID: 28400988; PMCID: PMC5362181.
Copy Download .nbib Format: NLM
Transient Elastography for the Detection of Liver Damage in Patients with HIV.

Infectious diseases and therapy

Sagir A, Glaubach B, Sahin K, Graf D, Erhardt A, Oette M, Häussinger D.
PMID: 26143457
Infect Dis Ther. 2015 Sep;4(3):355-64. doi: 10.1007/s40121-015-0073-y. Epub 2015 Jul 05.

INTRODUCTION: Highly active antiretroviral therapy (HAART) is effective and well tolerated, but hepatotoxicity is relatively common. Different non-invasive methods are available for detecting liver fibrosis in patients with chronic liver disease.METHODS: Patients who were HIV positive and who had...

Cite
Sagir A, Glaubach B, Sahin K, et al. Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infect Dis Ther. 2015;4(3):355-64doi: 10.1007/s40121-015-0073-y.
Sagir, A., Glaubach, B., Sahin, K., Graf, D., Erhardt, A., Oette, M., & Häussinger, D. (2015). Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infectious diseases and therapy, 4(3), 355-64. https://doi.org/10.1007/s40121-015-0073-y
Sagir, Abdurrahman, et al. "Transient Elastography for the Detection of Liver Damage in Patients with HIV." Infectious diseases and therapy vol. 4,3 (2015): 355-64. doi: https://doi.org/10.1007/s40121-015-0073-y
Sagir A, Glaubach B, Sahin K, Graf D, Erhardt A, Oette M, Häussinger D. Transient Elastography for the Detection of Liver Damage in Patients with HIV. Infect Dis Ther. 2015 Sep;4(3):355-64. doi: 10.1007/s40121-015-0073-y. Epub 2015 Jul 05. PMID: 26143457; PMCID: PMC4575292.
Copy Download .nbib Format: NLM
Current Options for the Therapy of Chronic Hepatitis B Infection.

Current infectious disease reports

Kioko Ono-Nita S, Kato N, Shiratori Y, Omata M.
PMID: 11286654
Curr Infect Dis Rep. 2001 Apr;3(2):137-142. doi: 10.1007/s11908-996-0036-2.

Until recently the only available treatment for chronic hepatitis B was interferon-alpha. Over the past few years a new class of antiviral has become available, the reverse transcriptase inhibitors. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor that was...

Cite
Kioko Ono-Nita S, Kato N, Shiratori Y, et al. Current Options for the Therapy of Chronic Hepatitis B Infection. Curr Infect Dis Rep. 2001;3(2):137-142doi: 10.1007/s11908-996-0036-2.
Kioko Ono-Nita, S., Kato, N., Shiratori, Y., & Omata, M. (2001). Current Options for the Therapy of Chronic Hepatitis B Infection. Current infectious disease reports, 3(2), 137-142. https://doi.org/10.1007/s11908-996-0036-2
Kioko Ono-Nita, Suzane, et al. "Current Options for the Therapy of Chronic Hepatitis B Infection." Current infectious disease reports vol. 3,2 (2001): 137-142. doi: https://doi.org/10.1007/s11908-996-0036-2
Kioko Ono-Nita S, Kato N, Shiratori Y, Omata M. Current Options for the Therapy of Chronic Hepatitis B Infection. Curr Infect Dis Rep. 2001 Apr;3(2):137-142. doi: 10.1007/s11908-996-0036-2. PMID: 11286654.
Copy Download .nbib Format: NLM
P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs.

Advanced drug delivery reviews

Aungst BJ.
PMID: 10837770
Adv Drug Deliv Rev. 1999 Oct 18;39(1):105-116. doi: 10.1016/s0169-409x(99)00022-8.

Orally administered anti-HIV drugs must be adequately and consistently absorbed for therapy to be successful. This review discusses the barriers to achieving oral bioavailability for the currently available anti-HIV drugs. Most reverse transcriptase inhibitors have good oral bioavailabilities. Didanosine...

Cite
Aungst BJ. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev. 1999;39(1):105-116doi: 10.1016/s0169-409x(99)00022-8.
Aungst, B. J. (1999). P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Advanced drug delivery reviews, 39(1), 105-116. https://doi.org/10.1016/s0169-409x(99)00022-8
Aungst. "P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs." Advanced drug delivery reviews vol. 39,1 (1999): 105-116. doi: https://doi.org/10.1016/s0169-409x(99)00022-8
Aungst BJ. P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs. Adv Drug Deliv Rev. 1999 Oct 18;39(1):105-116. doi: 10.1016/s0169-409x(99)00022-8. PMID: 10837770.
Copy Download .nbib Format: NLM
Comparison of Ritonavir in a First Choice Three Drug Regimen, After Two Nucleoside Analogues and in Saquinavir Experienced Patients.

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Aboudib LB, Santos EL, Cunha MP, Mochel A.
PMID: 11103013
Braz J Infect Dis. 1998 Oct;2(5):227-235.

Ritonavir is a potent, orally bioavailable inhibitor of HIV-1 protease. Our investigators undertook a retrospective study to compare the effectiveness of ritonavir (600mg twice daily) associated with 2 reverse transcriptase inhibitors (RTIs) in 38 patients in 3 situations. Group...

Cite
Aboudib LB, Santos EL, Cunha MP, et al. Comparison of Ritonavir in a First Choice Three Drug Regimen, After Two Nucleoside Analogues and in Saquinavir Experienced Patients. Braz J Infect Dis. 1998;2(5):227-235
Aboudib, L. B., Santos, E. L., Cunha, M. P., & Mochel, A. (1998). Comparison of Ritonavir in a First Choice Three Drug Regimen, After Two Nucleoside Analogues and in Saquinavir Experienced Patients. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, 2(5), 227-235.
Aboudib, et al. "Comparison of Ritonavir in a First Choice Three Drug Regimen, After Two Nucleoside Analogues and in Saquinavir Experienced Patients." The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases vol. 2,5 (1998): 227-235.
Aboudib LB, Santos EL, Cunha MP, Mochel A. Comparison of Ritonavir in a First Choice Three Drug Regimen, After Two Nucleoside Analogues and in Saquinavir Experienced Patients. Braz J Infect Dis. 1998 Oct;2(5):227-235. PMID: 11103013.
Copy Download .nbib Format: NLM
Human immunodeficiency virus protease inhibitors. From drug design to clinical studies.

Advanced drug delivery reviews

Lin JH.
PMID: 10837559
Adv Drug Deliv Rev. 1997 Sep 15;27(2):215-233. doi: 10.1016/s0169-409x(97)00044-6.

The discovery of human immunodeficiency virus (HIV) protease inhibitors is an example in which pharmacokinetic evaluation was implemented early in the discovery phase to obtain optimal pharmacological and pharmacokinetic properties. Currently, three HIV protease inhibitors, saquinavir, indinavir and ritonavir...

Cite
Lin JH. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv Drug Deliv Rev. 1997;27(2):215-233doi: 10.1016/s0169-409x(97)00044-6.
Lin, J. H. (1997). Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Advanced drug delivery reviews, 27(2), 215-233. https://doi.org/10.1016/s0169-409x(97)00044-6
Lin. "Human immunodeficiency virus protease inhibitors. From drug design to clinical studies." Advanced drug delivery reviews vol. 27,2 (1997): 215-233. doi: https://doi.org/10.1016/s0169-409x(97)00044-6
Lin JH. Human immunodeficiency virus protease inhibitors. From drug design to clinical studies. Adv Drug Deliv Rev. 1997 Sep 15;27(2):215-233. doi: 10.1016/s0169-409x(97)00044-6. PMID: 10837559.
Copy Download .nbib Format: NLM
Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study.

International journal of immunopathology and pharmacology

Gianotti N, Setti M, Manconi PE, Leoncini F, Chiodo F, Minoli L, Moroni M, Angarano G, Mazzotta F, Carosi G, Antonelli G, Lazzarin A.
PMID: 12590875
Int J Immunopathol Pharmacol. 2002 May-Aug;15(2):129-139. doi: 10.1177/039463200201500208.

Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) was studied in 527 HIV-1-infected patients, 342 responder and 185 non-responder to two NRTIs. Responders were followed for one year to assess the incidence of clinical failure. The prevalence of the 215Y/F...

Cite
Gianotti N, Setti M, Manconi PE, et al. Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. Int J Immunopathol Pharmacol. 2002;15(2):129-139doi: 10.1177/039463200201500208.
Gianotti, N., Setti, M., Manconi, P. E., Leoncini, F., Chiodo, F., Minoli, L., Moroni, M., Angarano, G., Mazzotta, F., Carosi, G., Antonelli, G., & Lazzarin, A. (2002). Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. International journal of immunopathology and pharmacology, 15(2), 129-139. https://doi.org/10.1177/039463200201500208
Gianotti, N., et al. "Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study." International journal of immunopathology and pharmacology vol. 15,2 (2002): 129-139. doi: https://doi.org/10.1177/039463200201500208
Gianotti N, Setti M, Manconi PE, Leoncini F, Chiodo F, Minoli L, Moroni M, Angarano G, Mazzotta F, Carosi G, Antonelli G, Lazzarin A. Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. Int J Immunopathol Pharmacol. 2002 May-Aug;15(2):129-139. doi: 10.1177/039463200201500208. PMID: 12590875.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 416 entries